Related Experiment Video
Updated: Aug 12, 2026
11:11
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Summary
Large cell anaplastic lymphoma, Ki-1 positive (a subtype of non-Hodgkin lymphoma) presents diagnostic challenges. Early diagnosis and intensive chemotherapy are crucial for managing this aggressive lymphoma.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Large cell anaplastic lymphoma, Ki-1 positive (ALCL) is a distinct non-Hodgkin lymphoma (NHL) subtype, comprising 1-8% of NHL cases.
- Diagnostic differentiation from Hodgkin's disease and true histiocytic lymphoma can be challenging, even for expert pathologists.
- ALCL is now recognized in the updated Kiel Classification of lymphomas.
Observation:
- Classical histological features include a sinusoidal growth pattern in lymph nodes and the presence of large, bizarre anaplastic cells.
- Immunophenotypic analysis using cell markers such as LCA, EMA, and Ki-1 (Ber-H2) is essential for accurate diagnosis.
- The mean patient age is 50 years, with approximately 50% presenting at advanced stages (III-IV).
Findings:
- Prognosis is influenced by patient age and tumor localization.
- Cutaneous involvement alone generally indicates a favorable prognosis.
- Median survival for patients with extra-cutaneous disease is 13 months.
Implications:
- Treatment typically requires intensive chemotherapy regimens.
- Long-term remissions are more commonly observed in pediatric and adolescent populations.
- Accurate diagnosis and staging are critical for effective treatment strategies in ALCL.
